NCM
ADAP

Narwhal Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Narwhal Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,344
Closed -$9.57K – 165
2023
Q2 		$9.57K Hold
10,344
– – ﹤0.01% 170
2023
Q1 		$11.3K Hold
10,344
– – ﹤0.01% 163
2022
Q4 		$15.1K Hold
10,344
– – ﹤0.01% 160
2022
Q3 		$11K Buy
+10,344
New +$19K ﹤0.01% 151

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Narwhal Capital Management's ADAP Position: Q3 2023 in Review

Narwhal Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 10,344 shares — an estimated $9.57K sold.

Narwhal Capital Management first reported a position in ADAP in Q3 2022 and held it in 4 quarters. The position peaked at $15.1K in Q4 2022. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Narwhal Capital Management reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Narwhal Capital Management sold 10,344 Adaptimmune Therapeutics shares in Q3 2023, an estimated $9.57K.
  • Narwhal Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2022 and held it in 4 quarters.
  • Narwhal Capital Management's Adaptimmune Therapeutics position peaked at $15.1K in Q4 2022.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Narwhal Capital Management's 13F filing for Q3 2023, filed 30 Oct 2023.